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Abstract
Introduction The objectives of this study were to estimate the economic burden of HPV in Italy, accounting for total direct 
medical costs associated with nine major HPV-related diseases, and to provide a measure of the burden attributable to HPV 
6, 11, 16, 18, 31, 33, 45, 52, 58 infections.
Methods A cost-of-illness incidence-based model was developed to estimate the incidences and costs of invasive cervical 
cancer, cervical dysplasia, cancer of the vulva, vagina, anus, penis, oropharyngeal, anogenital warts, and recurrent respira-
tory papillomatosis (RRP) in the context of the Italian National Health System (NHS). We used data from hospital discharge 
records (HDRs) of an Italian region and conducted a systematic literature review to estimate the lifetime cost per case, the 
number of incident cases, the prevalence of HPV9 types. Costs of therapeutic options not included in the diagnosis-related 
group (DRG) tariffs were estimated through a scenario analysis.
Results In 2018, the total annual direct costs were €542.7 million, with a range of €346.7–€782.0 million. These costs could 
increase considering innovative therapies for cancer treatment (range €16.2–€37.5 million). The fraction attributable to the 
HPV9 genotypes without innovative cancers treatment was €329.5 million, accounting for 61% of the total annual burden 
of HPV-related diseases in Italy. Of this amount, €135.9 million (41%) was related to men, accounting for 64% of the costs 
associated with non-cervical conditions.
Conclusions The infections by HPV9 strains and the economic burden of non-cervical HPV-related diseases in men were 
found to be the main drivers of direct costs.
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Introduction
Human papillomavirus (HPV) is the most common sexually 
transmitted virus and causes a substantial burden of dis-
ease in both men and women [1]. The prevalence of HPV 
remains unacceptably high. In 2013–2014, approximately 
45% of men and 40% of women between the ages of 18 and 
59 had genital HPV infection [2]. Genital HPV infections are 
contracted through unprotected vaginal or anal sexual inter-
course and skin-to-skin genital contact. HPV infections that 
result in oral or upper respiratory malignancies are mostly 
contracted through unprotected oral sex [3]. Most HPV 
infections are asymptomatic and resolve within a few months 
of exposure. However, the infection can progress to form 
pre-cancerous and cancerous lesions. HPV has been shown 
to be the cause of several clinically significant conditions. 
As of this writing, more than 100 types of papillomavirus 
strains that can infect humans have been identified. These 
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have been divided into high- and low-risk types according 
to their risk of progressing to cancer. The high-risk onco-
genic variants of HPV, specifically genotypes 16 and 18, 
account for approximately 70% of all cases of invasive cervi-
cal cancer and cervical dysplasia worldwide [4, 5]. They also 
account for a smaller fraction of cancers of the vulva, vagina, 
anus, penis, head and neck [6]. The low-risk HPV variants of 
genotypes 6 and 11 are responsible for approximately 90% 
of benign external anogenital warts [7] and almost all cases 
of recurrent respiratory papillomatosis (RRP) [8, 9].
Primary prevention of HPV-related diseases is possible 
with vaccination. Three vaccines (Cervarix, Gardasil and 
Gardasil9) are currently approved for the prevention of HPV 
infection. All of these vaccines are active against the high-
risk HPV 16 and 18 strains, while Gardasil® also protects 
against HPV 6 and 11. Gardasil9 was authorized in the 
European market in 2015 and protects against nine strains 
of HPV, including types 6, 11, 16, 18, 31, 33, 45, 52, and 
58 [10, 11]. The availability of these vaccines has led to the 
initiation of population-wide immunization programmes in 
most western countries. Based on previous cost-effective-
ness studies, the primary aim of most HPV immunization 
programmes has been to protect women against cervical 
cancer [12–14]. However, a study published in 2012 dem-
onstrated the relevance of the burden of HPV malignancies 
in men to all who pay for healthcare services (the Italian 
National Health System, NHS) [15]. A subsequent study 
demonstrated the cost-effectiveness of gender-neutral immu-
nization in Italy [14]. Based on these findings, in 2017, the 
Italian Government became the first of the G9 countries to 
introduce a universal, recommended and free vaccination for 
HPV for girls and boys at the age of 12 [16].
Because of these policy changes, the aim of the study 
was to provide an estimate of the total, direct medical costs 
attributable to HPV infection, with stratification of the bur-
den by sex as well as specific diseases using cost inputs 
taken from the Italian National Health Service. Furthermore, 
this study also calculated an aggregate measure of the total 
economic burden attributable to HPV 6, 11, 16, 18, 31, 33, 
45, 52 and 58 infections as an estimate of the potential sav-
ings due to the introduction of the nine-valent universal HPV 
vaccination programme.
Methods
Study design
The study design was developed using the Italian National 
Health Service (NHS), from which the cost inputs were 
selected. A systematic review of the literature was conducted 
to identify economic and epidemiological data related to 
each HPV-induced disease. The review was aimed to identify 
the best secondary data available to produce lifetime costs 
per case estimates. In particular we searched for epidemio-
logical data such as incidence and prevalence rates as well 
as direct cost estimates from the perspective of the Italian 
national payer. As a result, lifetime costs for cervical dys-
plasia, anogenital warts and cervical cancer were modelled 
based on a number of previously published studies (Table 1) 
[17]. Due to the lack of available information regarding RRP 
in the Italian context, treatment assumptions were speculated 
for this disease on the basis of international literature as well 
as tariffs applied by Italian diagnosis-related groups (DRGs).
Real-world data were used to estimate hospital-based 
management costs of the main HPV-induced malignancies: 
cervical, vulvar, vaginal, penile, head and neck cancer. Spe-
cifically, hospital discharge records (HDRs) from 2010 to 
2014 from the administrative archives of the Marche region 
were analysed to identify hospitalization rates as well as the 
costs associated with HPV-related diseases. This approach 
was followed and validated by previous publications made 
in this field [24]. Finally, outpatient costs related to these 
malignancies were estimated based on the latest national 
tariffs (2013) for specialist consultation procedures, and 
treatment paradigms were validated by the expert opinions 
of a group of clinicians. An incidence-based approach was 
then adopted to estimate lifetime costs per case and produce 
an aggregate measure of the economic burden. The relative 
prevalence rates of HPV types 6, 11, 16, 18, 31, 33, 45, 52, 
and 58 according to the literature were applied to estimate 
the aggregate fraction of costs attributable to HPV infec-
tions in Italy.
Real‑world data analysis
Information related to the hospital discharges (HDRs) of 
all accredited public and private hospitals in the Marche 
Region, both for ordinary and day-care regimens, were 
included to estimate the costs of cervical, vulvar, vaginal, 
penile, head and neck cancer. The total costs related to hos-
pitalizations were calculated using the DRGs (with 2013 val-
ues) of hospitalized patients based on their age, gender and 
their consumption of resources during their hospital stay. 
The DRG system aggregates all activities, including surgi-
cal interventions, administered drugs, expended materials 
and personnel for each individual diagnosis and stipulates 
the reimbursement tariff. This value corresponds to the total 
amount of all interventions provided that is to be paid to the 
hospital. According to the DRG-based reimbursement sys-
tem, every hospitalized patient was assigned to a group of 
diagnostically homogeneous cases; therefore, patients with 
the same DRG values were assigned the same reimburse-
ment charges.
We included hospitalizations of patients who were resi-
dents of the Marche region, were older than 18 years of 
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Table 1  Estimates of lifetime cost per patient by diagnosis
Diagnoses Surgical procedures and medical 
treatments
Direct cost per 
procedure or medical 
treatment
Compound 
inflation  ratea 
(%)
Lifetime direct cost 
per incident patient 
(2018 Euro)
Source
a b a × b
Cervical cancer
Management of primary tumour €13,122 117.50 €15,418 [17]
Discounted cost of progression/
recurrence after 1 year
€8827 117.50 €10,372 [17]
Lifetime cost per patient €21,949 €25,790
Cervical dysplasia
Abnormal PAP smears €25 117.50 €29 [18]
Colposcopies €101 117.50 €119 [18]
Diagnosis of cervical dysplasia €34 117.50 €40 [19]
CIN1 treatment €686 117.50 €806 [20]
CIN2 treatment €1242 117.50 €1459 [20]
CIN3 treatment €1763 117.50 €2072 [20]
Lifetime cost per patient €4011 €4525
Anal cancer (women)
Tot, lifetime hospitalizations €9607 109.30 €10,500 ICD9-CM (154.2–154.3; 
154.8)
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.7) [21]
Follow-up sector CT scan (×3) €74.88 102.20 €77 Outpatient tariff (87.03) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €9860 3 €11,570
Anal cancer (men)
Tot, lifetime hospitalizations €15,876 109.30 €17,353 ICD9-CM (154.2–154.3; 
154.8)
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.7) [21]
Follow-up sector CT scan (×3) €74.88 102.20 €77 Outpatient tariff (87.03) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €16,129 3 €18,422
Oropharyngeal cancer (women)
Tot, lifetime hospitalizations €11,210 109.30 €12,253 ICD9-CM (146.0–146.9) [21]
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.7) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €11,388 3 €13,029
Oropharyngeal cancer (men)
Tot, lifetime hospitalizations €23,096 109.30 €25,244 ICD9-CM (146.0–146.9)
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.7) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €23,274 3 €26,021
Vulvar and vaginal cancer
Tot, lifetime hospitalizations €11,084 109.30 €12,115 ICD9-CM (184.0–184.4; 
184.8–184.9)
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age, and who presented one of the following codes from 
the International Classification of Diseases, 9th revision-
Clinical Modification (ICD-9-CM) as the primary or second-
ary diagnosis: ‘Anal cancers’ (154.2–154.8); ‘Oropharyn-
geal cancers’ (146.0–146.9); ‘Other female genital organs’ 
(184.0–184.9); and ‘Penile cancer’ (187.1–187.9). A cohort 
of 810 patients (40% male and 60% female) who were hos-
pitalized in 2010 or 2011 was selected from those who did 
not fall into any of the reported ICD9-CM diagnosis catego-
ries and who had not had other malignant tumours in the 
2 years prior to their first hospital admission (naïve). Sub-
jects were included and then followed for 3 years after their 
first hospital admission. Based on expert opinions and [15], 
we assumed that a 3-year period was appropriate in terms 
of resource utilization to estimate lifetime costs. In addi-
tion, outpatient visits were modelled based on the clinical 
CIN cervical intra-epithelial neoplasia, RRP recurrent respiratory papillomatosis, CT computed tomography, Tot total, prob probability
a Costs have been adjusted for 2018 inflation values using the compound annual Italian National Consumer Price Indexes [23] from 2005 
(119.8%), 2006 (117.5%), 2010 (109.3%), and 2013 (102.2%)
Table 1  (continued)
Diagnoses Surgical procedures and medical 
treatments
Direct cost per 
procedure or medical 
treatment
Compound 
inflation  ratea 
(%)
Lifetime direct cost 
per incident patient 
(2018 Euro)
Source
a b a × b
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.26) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €11,262 3 €12,890
Penile cancer
Tot, lifetime hospitalizations €7031 109.30 €7685 ICD9-CM (187.1–187.9)
Follow-up 2 clinical examinations 
(×3)
€20.66 102.20 €42 Outpatient tariff (89.7) [21]
Follow-up sector CT scan (×3) €77.67 102.20 €79 Outpatient tariff (87.41) [21]
Follow-up sector CT scan (×3) €79.47 102.20 €81 Outpatient tariff (88.01) [21]
Lifetime cost per patient €7209 3 €8461
Anogenital warts (women)
Direct outpatient costs for new 
patients
€368 119.80 €441 [22]
Discounted cost of recurrence 
after 1 year (50.6% prob)
€176 119.80 €211 [22]
Discounted cost of resistance 
after 1 year (28.2% prob)
€43 119.80 €52 [22]
Lifetime cost per patient €587 €703
Anogenital warts (men)
Direct outpatient costs for new 
patients
€275 119.80 €329 [22]
Discounted cost of recurrence 
after 1 year (34.8% prob)
€59 119.80 €71 [22]
Discounted cost of resistance 
after 1 year (38.5% prob)
€82 119.80 €98 [22]
Lifetime cost per patient €416 €498
RRP
Management of complicated 
throat infection
€5744 102.20 €5870 DRG 79
Acute clinical treatment of throat 
infection (×3)
€9650 102.20 €29,587 DRG 76
Minor throat surgery (×4.4) €4378 102.20 €19,687 DRG 63
Tracheostomy (11% rate) €8737 102.20 €982 DRG 75
Annual cost per patient €28,509 €56,126
Lifetime cost per patient 3 €224,860
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pathway followed by [21] which was validated here by the 
clinical experts involved in the study. In particular based 
on the clinical guidelines and current practices, a number 
of procedures per each diagnose was established to repre-
sent the amount of outpatient services provided to patients 
lifetime. Outpatient costs were then applied based on the 
2013 national tariffs for specialists’ office consultations and 
procedures [15].
Literature review
Secondary data were identified through a systematic litera-
ture review. The search was carried out according to the 
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines [25] (Fig. 1). The search 
was conducted in October 2017 and covered the period 
1990–2017. The analysis was performed through the online 
MEDLINE (Medical Literature Analysis and Retrieval Sys-
tem) bibliographic archive of MEDLARS using the PubMed 
search system and EMBASE accessed through OVID SP. To 
retrieve robust data that were relevant to Italy, the inquiry 
was integrated with grey literature obtained from generic 
academic search engines (e.g., Google Scholar) and websites 
such as the Italian Ministry of Health, the Italian National 
Institute of Health (NIH), and those of Italian scientific 
societies such as the Italian Society of Health Technology 
Assessment (SIHTA). The search keys used to conduct the 
literature are reported in Annex B.
Screening and data extraction
Two independent researchers screened the titles and 
abstracts. Full-text articles were included if they met the 
following inclusion criteria: (1) they reported epidemiologi-
cal data (incident cases by disease and the prevalence of 
HPV by genotype) derived from population databases, such 
as national surveys or registries; and (2) they reported direct 
cost data from the perspective of the payer and expressed 
monetary values for hospital DRGs and outpatient tariffs. 
Studies were also required to contain estimates of reported 
lifetime costs or appropriate data to estimate these costs. 
For all phases of the literature review, disagreements were 
Fig. 1  Literature review, 
PRISMA
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resolved by discussions among the entire team to reach a 
consensus.
Lifetime costs
An incidence-based approach was adopted in which the 
lifetime costs per case associated with each condition were 
applied to the estimated number of incident cases that were 
attributable to HPV. We sought to develop cost-per-case esti-
mates that represented the current values of the total direct 
medical costs accrued from the time of diagnosis to the end 
of follow-up (Table 1).
Specifically, cost estimates for cervical cancer were 
obtained from a published Italian study [17] that estimated 
the mean total direct costs for cervical cancer, including 
those generated by the management of disease progression 
and recurrence. The actual costs were not reported, although 
the median follow-up duration of the cohort was 23 months 
(range 1–89). We assumed that the mean cost per patient for 
primary tumour treatment (€13,122) was incurred within 
year 1, whereas the mean cost associated with the manage-
ment of disease progression and recurrence (€9092) was 
incurred in the following year, and we reduced this second-
year value by 3% (€8827). The selected discount rate (3%) 
reflects the opportunity costs of financing from the perspec-
tive of a public payer (the Italian NHS) according to Italian 
AIES (Italian Health Economics Association) guidelines 
[26].
Lifetime costs associated with the clinical and surgical 
management of cervical dysplasia were estimated from pub-
lished Italian data [18, 19].
The lifetime cost per patient of non-cervical malignan-
cies was modelled on the national treatment guidelines of a 
previously published study [15]. Therefore, in addition to the 
real-world data used to estimate the lifetime costs of hospi-
talization, we also included two clinical examinations con-
ducted by specialists and two two-sector computed tomogra-
phy (CT) scans per year. These costs were then reported over 
a 3-year follow-up period, which is consistent with the real-
world data according to [15] and expert opinion. Outpatient 
fees were attributed to each surgical procedure and medical 
treatment using national outpatient tariff values (2013). Hos-
pitalization costs (including outpatient costs) incurred after 
the first 12 months of treatment were discounted at a rate of 
3% per year to obtain their current net value expressed in the 
value of the Euro in 2013.
The estimated lifetime cost of anogenital warts per inci-
dent case was calculated as the sum of the mean, inflation-
adjusted direct costs incurred by new patients (€416 for 
women and €311 for men) and the probable, discounted, 
inflation-adjusted mean direct costs of recurrent (€199 for 
women and €66 for men) and resistant (€48 for women and 
€92 for men) episodes observed over 1 year after initial 
diagnosis. These figures were modelled on a previously 
published article [22]. Probability rates were calculated 
based on the number of recurrent (50.6% for women and 
34.8% for men) and resistant (28.2% for women and 38.5% 
for men) cases reported as a percentage of the annual num-
ber of newly diagnosed cases, assuming a steady state in the 
total number of genital warts treated in Italy [22].
Finally, to estimate the lifetime cost per RRP patient, 
elective surgical procedures and medical treatments were 
selected according to published reports from the US [27, 
28]. Treatment assumptions included the management of 
complicated respiratory infections, three acute clinical treat-
ments, 4.4 surgical procedures, and a tracheotomy rate of 
11% per year [27]. Italian DRG tariffs for 2013 were applied 
to the selected procedures. The duration of the disease was 
estimated to be 4.2 years [27]. All costs incurred after the 
first 12 months of treatment were discounted at a rate of 3% 
per year to obtain their current net value expressed in the 
value of the Euro in 2013.
All costs related to each HPV-induced disease included 
in the study (Table 1) were adjusted for inflation in 2018 
using the compound annual Italian National Consumer Price 
Indexes (NIC) provided by the Italian National Institute of 
Statistics (ISTAT).
Incidence and HPV9 genotype attribution
An estimate of the incident cases in the population over 
18 years of age in Italy in 2018 [29] was obtained from the 
systematic literature review using the mean of the ranges 
provided by the selected studies. Crude incident rates per 
100,000 residents in the 2018 resident Italian population 
[29] were calculated (Table 2). Due to the heterogeneity of 
the rates reviewed and the number of diseases involved, no 
standardization, meta-analyses or adjustments for the pyram-
idal stratification of the observed population were attempted. 
Due to a lack of Italian epidemiological data, the incidence 
of RPP was deliberately selected from the lower limit of the 
range cited in the literature [15].
Moreover, to estimate the costs attributable to HPV types 
6, 11, 16, 18, 31, 33, 45, 52 and 58, prevalence rates of HPV 
DNA and genotype attribution per condition were identified 
from the systematic review. Specifically, for each condition, 
we first calculated the percentage of DNA attribution to 
exclude all cases that were not a result of HPV infection. We 
then applied prevalence rates from the literature to calculate 
the individual fractions attributable to genotypes included in 
HPV9 vaccine (Table 3 and Annexe A). These values were 
used to calculate the fraction of the total economic burden 
of HPV-induced malignancies attributable to the nine geno-
types by both disease and sex according to the number of 
estimated incident cases.
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Statistical analyses
Probabilistic and Deterministic Sensitivity Analyses (PSA 
and DSA) were developed to account for the variability of 
data used in the model. The PSA employed the differences 
found in the examined sources indicating minimum and max-
imum values of the uncertainty distribution for each param-
eter. The probabilistic distribution was prepared by applying 
normally reported values for the development of probabilis-
tic models in economic evaluations, distinguishing between 
costs (gamma distribution) and epidemiological parameters 
(beta distribution) [41]. The distribution of each parameter 
was then used to perform 5000 Monte Carlo simulations to 
obtain interval estimates (95% confidence interval (CI)) for 
the main epidemiological and economic data (Annex C).
The DSA was performed by adjusting each parameter to 
the highest and lowest possible values of the data obtained 
from the systematic review with a one-way approach. When 
a plausible range was not available from the literature, we 
assumed a variation of 10%.
The critical parameters used to assess the uncertainty 
were: the number of incident cases per year, the HPV 6, 11, 
16, 18, 31, 33, 45, 52 and 58, genotype attributions and cost 
parameters. We measured the impact of inserting the highest 
and lowest values for: (1) all diseases, (2) only oncologic 
diseases (defined as the sum of cervical, anal, oropharyn-
geal, vulvar, vaginal and penile cancers) (3) non-oncologic 
(cervical dysplasia, anogenital warts and RRP).
Cost estimates of innovative therapeutic options 
not included in the DRG tariffs
The DRG tariffs used as the main inputs for evaluating the 
direct costs of hospitalization did not include the costs of 
innovative therapeutic options that were added to the treat-
ment guidelines for HPV-induced malignancies after 2013. 
The costs of these new drugs were actually debited to a 
National Account (named “File F”), which was specifically 
created to account for highly innovative therapeutic options. 
However, the administrative costs were paid for by the DRG 
tariff. File F is not accessible and does not provide informa-
tion on the use of innovative drugs by indication. There-
fore, identifying the resources allocated from File F used 
to treat HPV-induced malignancies is impossible. Ignoring 
these costs, however, would significantly underestimate 
the burden of HPV-induced diseases carried by the NHS. 
Therefore, we used the scenario analysis [42] method to 
estimate a range of credible costs for the innovative thera-
pies used to treat HPV-induced malignancies. Following the 
latest guidelines of the Associazione Italiana di Oncologia 
Medica (AIOM) for the treatment of HPV-induced malig-
nancies, two innovative therapeutic options were identified:
• Cetuximab (Erbitux), indicated for the treatment of head 
and neck cancer;
• Bevacizumab (Avastin), indicated for the treatment of 
recurrent or refractory cervical cancer.
The treatment and cost inputs used to determine the three 
scenarios are reported in Annex A.
Results
The annual incidence of the nine HPV-related conditions 
corresponded to approximately 1.1 million cases of which 
975,000 associated to cervical conditions (86%), and 
158,000 to non-cervical (14%). In 2018, the total direct 
Table 2  Incidence rates, the 
prevalence of HPV, and HPV9 
genotype fractions
CIN cervical intra-epithelial neoplasia, RRP recurrent respiratory papillomatosis
Diagnoses Incidence rates 
(per 100,000)
HPV DNA+ (%) HPV9 frac-
tion (%)
Source
Cervical cancer 4.5 100.0 89.4 [30–32]
Abnormal PAP smears 699.2 100.0 91.5 [15]
Colposcopies 195.4 100.0 94.0 [15]
Diagnosis of cervical dysplasia 657.1 100.0 35.0 [15]
CIN1 treatment 35.9 100.0 75.0 [15, 32, 33]
CIN2 treatment 9.1 100.0 72.5 [15, 32, 33]
CIN3 treatment 10.0 100.0 57.2 [15]
Anal cancer 1.7 88.0 89.8 [30, 34]
Oropharyngeal cancer 15.5 40.0 73.7 [35, 36]
Vulvar and vaginal cancer 2.3 36.6 86.4 [31]
Penile cancer 0.8 50.0 81.6 [30, 37]
Anogenital warts 241.6 100.0 90.0 [15, 34]
RRP 0.4 100.0 95.0 [38–40]
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costs (expressed relative to the 2018 Euro) associated with 
the annual incident cases of cervical cancer, cervical dys-
plasia, vulvar, vaginal, anus, penis and head and neck can-
cers, anogenital warts, and RRP in Italy were estimated to be 
€542.7 million, with a credible range of €346.7–€782.0 mil-
lion. These costs could increase considering also the impact 
of innovative therapies for cancers treatment included in the 
scenario analysis with a plausible range between €16.2 and 
€37.5 million. The fraction attributable to the nine HPV9 gen-
otypes included in our base case analysis, without considering 
the impact of innovative therapies, was €329.5 million (range 
€157.0–€564.9 million), accounting for approximately 61% 
of the total annual burden of HPV-related diseases in Italy.
Cervical conditions
The total cost estimate for cervical conditions was 
€149.9 million (range €132.0–€168.9 million), which corre-
sponds to 28% of the total economic burden associated with 
HPV-related diseases in Italy, (Table 3). Of this amount, 
€69.7 (range €59.1–€81.2 million) and €80.2 million (range 
€66.2–€95.6 million) were due to cervical cancer and total 
cervical dysplasia, respectively—estimates that include 
diagnosis, colposcopies, PAP smears and cervical neopla-
sia (CIN1/2/3). Additionally, the total annual cost associated 
with the management of cervical lesions, including the diag-
nosis and treatment of CIN1/2/3 stages, was €54.0 million 
(range €41.0–€68.7 million).
The fraction of cervical conditions attributable to HPV 
types 6, 11, 16, 18, 31, 33, 45, 52 and 58 was estimated to 
be €118.3 million (range €104.2–€133.3 million), 53% of 
which was related to cervical cancers (€62.3 million, range 
€52.6–€72.8).
Non‑cervical malignancies
We evaluated the direct costs related to the treatment and 
follow-up of HPV-related cases of seven non-cervical 
Table 3  Total lifetime costs and HPV-9 attributable fraction
Diagnoses Estimated number of incident cases 
per year
Total lifetime direct 
costs per disease (mill 
Euro)
HPV9 attributable costs (mill Euro)
a Cervical cancer (CI 95%) 2698 (2502–2902) €69.7 (€59.1–€81.2) €62.3 (€52.6–€72.8)
b Abnormal PAP smears (CI 95%) 422,922 (345,068–507,585) €12.3 (€9.1–€15.8) €11.2 (€7.8–€15.1)
c Colposcopies (CI 95%) 118,214 (95,649–142,480) €14.0 (€10.3–€18.2) €13.1 (€9.1–€17.8)
d Diagnosis of cervical dysplasia (CI 
95%)
397,444 (321,588–480,112) €15.9 (€11.7–€20.6) €5.6 (€3.8–€7.6)
e CIN1 treatment (CI 95%) 21,715 (17,706–26,141) €17.5 (€13–€22.6) €13.1 (€9.3–€17.6)
f CIN2 treatment (CI 95%) 5532 (1998–10,735) €8.0 (€2.8–€16) €5.8 (€1.9–€11.8)
g CIN3 treatment (CI 95%) 6047 (2290–11,646) €12.6 (€4.5–€24.6) €7.2 (€2.5–€14.4)
h Total cervical lesions (d + e + f + g) 
(CI 95%)
430,738 (35,4125–513,625) €54.0 (€41–€68.7) €31.7 (€23.3–€41.3)
i Total cervical dysplasia (b + c + h) 
(CI 95%)
971,874 (857,453–1,090,683) €80.2 (€66.2–€95.6) €56.0 (€46–€67.1)
l Total cervical conditions (a + i) (CI 
95%)
974,572 (860,140–1,093,375) €149.9 (€132–€168.9) €118.3 (€104.2–€133.3)
m Anal cancer (women) (CI 95%) 620 (528–720) €7.2 (€5.6–€8.9) €5.7 (€4.3–€7.3)
n Anal cancer (men) (CI 95%) 437 (360–522) €8.0 (€6.1–€10.3) €6.4 (€4.6–€8.4)
o Oropharyngeal cancer (women) (CI 
95%)
2200 (2168–2232) €28.7 (€23.6–€34.3) €8.4 (€6.4–€10.8)
p Oropharyngeal cancer (men) (CI 
95%)
7200 (7184–7216) €187.0 (€153.3–€224.1) €55.1 (€41.2–€70.9)
q Vulvar and vaginal cancer (CI 95%) 1418 (1275–1566) €18.3 (€14.6–€22.3) €5.8 (€4.4–€7.3)
r Penile cancer (CI 95%) 494 (411–582) €4.2 (€3.2–€5.3) €1.7 (€1.3–€2.2)
s Anogenital warts (women) (CI 95%) 63,447 (51,697–76,430) €44.6 (€34.5–€56) €40.1 (€28.5–€53.6)
t Anogenital warts (men) (CI 95%) 82,674 (67,432–99,496) €41.2 (€32.1–€51.5) €37.1 (€26.4–€49.5)
u RRP (CI 95%) 249 (0–1660) €53.6 (€0–€372.8) €51.0 (€0–€356)
v Total non-cervical conditions (m + n 
+ o + p + q + r + s + t + u) (CI 95%)
158,739 (139,079–179,749) €392.9 (€206.3–€638.4) €211.2 (€58.5–€460.1)
z Total burden (l + v) (CI 95%) 1,133,312 (1,016,911–1,253,343) €542.7 (€346.7–€782) €329.5 (€157–€564.9)
CIN cervical intra-epithelial neoplasia, RRP recurrent respiratory papillomatosis
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malignancies: cancer of the anus, oropharynx, vulva, vagina, 
and penis, anogenital warts and RPP. The economic burden 
associated with non-cervical conditions was €392.9 million, 
with a range of €206.3–€638.4 million. The amount corre-
sponds to 72% of the total costs associated with HPV-related 
diseases in Italy. Oropharyngeal cancers were responsible for 
the highest annual burden of direct costs (€215.7 million, 
€187.0 for men and €28.7 for women), followed by anogeni-
tal warts (€85.9 million, €41.2 for men and €44.6 for women) 
and RPP (€53.6 million). The costs related to all HPV-related 
diseases included in our study are reported in Table 3.
According to our systematic review, HPV virus were 
responsible for 36.6% of vulvar and vaginal cancers and 40% 
of oropharyngeal cancers, respectively, as well as 88% and 
50% [30] of anal and penile cancers, respectively. The esti-
mated fractions of the total annual direct costs attributable to 
HPV 6, 11, 16, 18, 31, 33, 45, 52 and 58-induced non-cervical 
malignancies were €211.2 million (range €58.5–€460.1 mil-
lion), 61% of which was attributable to HPV 6 and 11.
Cost of innovative therapies not included in DRG 
tariffs
Table 4 reports the outcomes of the scenario analysis. Three 
scenarios were obtained by varying the potential number of 
patients treated and the future availability of similar treat-
ments at a reduced price. The credible range of the incremen-
tal costs allocated to innovative treatments of HPV-induced 
malignancies was €16.2–€37.5 million. This range represents 
a significant incremental cost compared to the DRG tariffs for 
the HPV-induced malignancies, ranging from 12.8 to 29.8%.
The availability of similar therapies would reduce the 
incremental cost by approximately 22%.
The fraction of HPV9-genotype costs attributable to men 
was equal to €137.7, while women accounted for €194.4. 
This corresponded to 58% of total costs attributable to HPV9 
infections for women, whereas men accounted for 42%. On 
the other hand, the economic burden of HPV 6, 11, 16, 18, 
31, 33, 45, 52 and 58 infections that were related to non-
cervical conditions was higher for men than women (64.4% 
vs 35.6% of the total, respectively) (Fig. 2).
The Tornado chart shown in Fig. 3 shows that the uncer-
tainty in our evaluation of the economic burden of HPV9-
related diseases is mostly associated with the range of pos-
sible incidence rates for all groups of disease and costs.
Discussion
The purpose of this analysis was to estimate the eco-
nomic burden of HPV-related diseases in Italy. Our study 
attempted to measure the direct costs from the real-world 
data perspective of the Italian National Health Service. The 
authors adopted a real-world data approach to estimate life-
time costs and conducted a systematic literature review to 
construct our estimation models with the most recent data 
available. Additionally, we included the nine HPV genotypes 
included in the new nine-valent vaccine that was made avail-
able in Europe in the last 2 years. Therefore, the present 
study is a first attempt to measure the economic burden of 
HPV-related diseases in Italy considering the newly avail-
able vaccine and data. By estimating the resource consump-
tion attributable to the nine genotypes, we aim to predict the 
effects of both the 2017–2019 National Immunization Plan 
and the strategies recently adopted in Italy and to inform 
future public health decisions.
According to the results of this study, costs related to 
CIN1 treatment, vaginal cancer and cervical cancer were 
the most heavily influenced when including five HPV geno-
types that accounted for 28% of their total cost on average. 
Furthermore, the economic burden among men represented 
more than one-third (42%) of the total direct costs of HPV9 
genotype-related diseases, including cervical conditions, 
which is consistent with previously published data [6, 15] 
and with the effort to extend the anti-HPV immunization 
programme to include boys in the National Immunization 
Plan 2017–2019.
The present study has several limitations. First, real-world 
data from administrative archives were only available for 
anal, head and neck, vulvar, vaginal and penile cancers, and 
published Italian sources of cost data were limited. Addi-
tionally, the quality of the available information was vari-
able. Therefore, the use of different data sources may have 
diminished the comprehensiveness of our data. Specifically, 
the use of administrative data required certain assumptions 
to consistently estimate the lifetime costs from different data 
sources. Hospital discharge forms may have codification 
problems; therefore some information may be missing and/
or be wrongly reported. In this case, our analysis may have 
missed this information (due to the inclusion criteria), with 
the risk of underestimating the economic and epidemiologi-
cal burden of the considered HPV-related diseases. Addi-
tionally, not all diseases led to hospitalization and this may 
be a further source of underestimation. Additionally, due to 
the scarcity of available data, we did not include drug utili-
zation in our estimates. These limitations should be consid-
ered in future research; however, in our opinion, they do not 
undermine the validity of the cost estimates in the present 
study or their estimated impact on the total economic bur-
den of HPV-related diseases. Future research should address 
these gaps in epidemiological and cost data to reduce the 
uncertainty associated with the present estimates. In conclu-
sion, the present analysis is the first to provide a snapshot 
of the current state of resource utilization in Italy and the 
expected economic effects resulting from the 2017–2019 
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Table 4  Credible range of incremental direct costs of the innovative therapies not included in DRG tariffs
OPC oropharyngeal cancer, C cetuximab, RT radiation therapy, CT chemotherapy, VEGF vascular endothelial growth factor, CC cervical cancer
Base case: 
(HPV9 
burden)
Scenario 1: CRT 
H&N + bevacizumab 
recurrent CC
Scenario 2: CRT + CCT in 
H&N + bevacizumab for 
recurrent and metastatic CC
Scenario 3: = Scenario 2 but 
biosimilars available (25% 
off)
Source
Base case—oropharyngeal cancer
 Incident patients infected by 
HPV9-susceptible strains
2771 2771 2771 2771
 Cost/patient €22,980 €22,980 €22,980 €22,980
 Total cost (Euro mill) €63.7 €63.7 €63.7 €63.7
Incremental cetuximab scenarios
 Cetuximab + RT in 
patients > 70 years (28% 
of total eligible)
776 776 776
 Incremental cost of Cetuxi-
mab added to RT/patient
€8133 €8133 €6133 [43]
 Total incremental cost 
(Euro mill)
€6.3 €6.3 €4.8
 Cetuximab + CT in Stage 
III–IV patients in good 
performance condition 
(80%)
€443.4 €443.4
 Incremental cost of cetuxi-
mab added to CT/patient
€5201.0 €3907.3 [43]
 Total incremental cost 
(Euro mill)
€2.3 €1.7
Base case—cervical cancer
 Incident patients infected by 
HPV9-susceptible strains
2412 2412 2412 2412
 Treatment cost/patient €25,790 €25,790 €25,790 €25,790
 Total cost (Euro mill) €62 €62 €62 €62
Incremental bevacizumab scenarios
 Incident cervical patients 
HPV9 + and VEGF+ 
(60% of incident)
€1447 €1447 €1447 [44]
 Recurrent patients (31% of 
incident VEGF+)
€449 €449 €449 [45]
 Incremental cost of bevaci-
zumab added to CT
€21,966 €21,966 €16,475
 Total incremental cost 
(Euro mill)
€10 €10 €7
 Metastatic patients (60% of 
incident VEGF+)
€868 €868 [45]
 Incremental cost of bevaci-
zumab added to CT
€21,966 €16,475 [46]
 Total incremental cost 
(Euro mill)
€19.07 €14.31
Total treatment cost per scenario (Euro mill)
 Incremental cost vs base 
case (Euro mill)
€125.9 €142.1 €163.4 €154.1
 Incremental cost as a % of 
base case
€16.2 €37.5 €28.2
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National Immunization Plan. Therefore, we believe that 
this analysis may provide a tool for keeping records of the 
expected economic effects over time.
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